Miltefosine: (Moderate) xarelto Caution is advised when administering miltefosine with ultima anticoagulants, as use of these dose drugs together may dose increase risk for bleeding.
In addition, both vilazodone and warfarin are highly protein bound, nescafe which may result in reduction displacement of warfarin from protein binding sites and an increased anticoagulant effect.
The use of other procoagulant reversal agents like activated prothrombin complex concentrate (apcc) or recombinant factor VIIa (rfviia) has not been evaluated.Usual Adult Dose of Xarelto for Deep dose Vein Thrombosis: Treatment of DVT xarelto and PE: Initial dose: 15 mg orally twice daily with food, store for first 21 days.Elagolix is an inhibitor of P-gp, and rivaroxaban is a substrate of P-gp.Adjust dose or discontinue use in patients who develop acute renal failure while on rivaroxaban.In a single-dose drug interaction study, no pharmacokinetic interactions were observed after concomitant administration of acetylsalicylic acid (aspirin, ASA) with rivaroxaban.Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) and Reduction in the Risk of Recurrence of DVT and PE CrCl less than 30 mL/minute: Avoid use due to an expected increase in rivaroxaban exposure and pharmacodynamic effects.Kava Kava, Piper methysticum: (Moderate) Kava kava, Piper methysticum does appear to have some anti-thrombotic activity.Weigh the risk of bleeding against the risk of thrombotic events in deciding whether to initiate rivaroxaban therapy in patients at increased risk of bleeding.Tretinoin, atra: (Moderate) An additive risk of bleeding may be seen in thrombocytopenic patients receiving antineoplastic agents in combination with anticoagulants.The change in bleeding time was approximately twice the maximum increase seen with either drug alone.Salicylates: (Major) Salicylates such as aspirin are known to increase bleeding, and bleeding risk may be increased when these drugs are used concomitantly with rivaroxaban.Methyltestosterone: (Moderate) Methyltestosterone can increase the effects of anticoagulants through reduction of procoagulant factor.Lomustine, ccnu: (Moderate) Due to the bone marrow suppressive and thrombocytopenic effects of lomustine, an additive risk of bleeding may be seen in patients receiving concomitant anticoagulants. Indinavir, a strong CYP3A4 inhibitor, is typically given in combination with ritonavir, a combined P-gp and strong CYP3A4 inhibitor.
An in vitro compatibility study indicated that there is no adsorption of rivaroxaban from a water dose reduction suspension of a crushed xarelto tablet to PVC or silicone nasogastric (NG) tubing.
Rofecoxib: (Major) An additive risk of bleeding may be seen in patients receiving anticoagulants in combination with other agents known to increase the risk of bleeding such as nonsteroidal antiinflammatory dose drugs (nsaids).
Similar increases basket in pharmacodynamic effects such as factor Xa inhibition and PT prolongation were also observed.If coadministration of these agents reduction with rivaroxaban reduction continues, closely monitor patients.Maintenance dose: 20 mg orally once daily reduction with food, for remaining treatment.Esterified Estrogens; Methyltestosterone: (Moderate) Methyltestosterone can increase the effects of anticoagulants through reduction of procoagulant factor.Ethanol: (Minor) reduction Use rivaroxaban cautiously in patients who consume alcohol.Oral reduction dosage, adults 10 mg PO once daily reduction after at least 6 laitiere months of standard anticoagulant therapy.Telithromycin cellulite is a combined P-gp inhibitor and strong CYP3A4 inhibitor.Discuss pregnancy planning with females of reproductive potential requiring cellulite anticoagulation.Exposure is further reduced when drug dose is released in the distal small intestine dose or ascending colon.Coadministration of betrixaban and other anticoagulants may increase the risk of bleeding.Dextromethorphan; Quinidine: (Minor) Coadministration of rivaroxaban and quinidine may result in increases in rivaroxaban exposure bestway and may increase bleeding risk.Ivacaftor: (Minor) The coadministration of rivaroxaban and ivacaftor should be undertaken with caution in patients with renal reduction impairment; it is unclear whether a clinically significant interaction occurs when these two drugs are coadministered to patients with normal renal function. Discontinuing rivaroxaban puts patients at an increased risk of thrombotic events.
Tezacaftor; Ivacaftor: (Minor) The coadministration of rivaroxaban and dose ivacaftor should be undertaken with caution in patients with renal impairment; it is unclear whether a clinically significant interaction occurs when these two drugs are coadministered to patients with normal renal function.
Apixaban: (Major) Avoid concurrent use of rivaroxaban with apixaban due to the increased bleeding risk.
Ethinyl Estradiol; Norethindrone Acetate: (Minor) Coadministration of rivaroxaban and ethinyl estradiol may result in increases in rivaroxaban exposure and may increase bleeding risk.